Gilead Sciences, Inc. $GILD Shares Bought by Trek Financial LLC

Trek Financial LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 282.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,949 shares of the biopharmaceutical company’s stock after buying an additional 46,509 shares during the quarter. Trek Financial LLC’s holdings in Gilead Sciences were worth $9,383,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Walled Lake Planning & Wealth Management LLC boosted its holdings in Gilead Sciences by 1.1% in the 3rd quarter. Walled Lake Planning & Wealth Management LLC now owns 54,879 shares of the biopharmaceutical company’s stock worth $8,180,000 after buying an additional 603 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Gilead Sciences by 22.3% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,038,316 shares of the biopharmaceutical company’s stock valued at $155,188,000 after acquiring an additional 189,152 shares during the last quarter. Virtue Capital Management LLC lifted its position in shares of Gilead Sciences by 12.8% in the third quarter. Virtue Capital Management LLC now owns 3,151 shares of the biopharmaceutical company’s stock valued at $470,000 after acquiring an additional 357 shares in the last quarter. Greenleaf Trust lifted its position in shares of Gilead Sciences by 0.6% in the third quarter. Greenleaf Trust now owns 24,345 shares of the biopharmaceutical company’s stock valued at $3,629,000 after acquiring an additional 157 shares in the last quarter. Finally, Leonard Rickey Investment Advisors P.L.L.C. purchased a new position in shares of Gilead Sciences in the third quarter valued at approximately $220,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on GILD. Morgan Stanley raised their price objective on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a report on Friday. TD Cowen upped their target price on shares of Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a report on Friday. Citigroup increased their target price on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research report on Friday. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Bank of America boosted their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $169.19.

Gilead Sciences Price Performance

Shares of GILD opened at $170.68 on Monday. Gilead Sciences, Inc. has a 52-week low of $114.02 and a 52-week high of $175.65. The company has a quick ratio of 0.95, a current ratio of 1.32 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $150.87 and a two-hundred day simple moving average of $139.79. The company has a market capitalization of $211.63 billion, a PE ratio of -54.01 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the previous year, the company posted $2.47 EPS. The company’s revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -1.03 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio is -103.80%.

Insiders Place Their Bets

In other news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00. Following the sale, the chief executive officer directly owned 566,683 shares in the company, valued at approximately $83,812,415.70. The trade was a 2.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 96,000 shares of company stock worth $13,923,210. 0.30% of the stock is currently owned by company insiders.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Several analysts raised their price targets for Gilead, setting targets of $175, $181, $183, $188, $190, and $200, while another raised its target to $131. The cluster of increases suggests improving confidence in Gilead’s earnings outlook and valuation. Gilead price target raised to $190 Gilead price target raised to $175 Gilead price target raised to $131 Gilead price target raised to $188 Gilead price target raised to $200 Gilead price target raised to $183 Gilead price target raised to $181
• Positive Sentiment: Morgan Stanley reiterated a Buy view on Gilead, adding to the positive analyst sentiment and supporting the case that the company’s HIV franchise and broader pipeline can sustain growth. Gilead receives a Buy from Morgan Stanley
• Positive Sentiment: Recent coverage points to strong HIV drug sales as a key reason GILD reached new highs. A separate investment article also highlighted Gilead as an attractive dividend-paying biotech, reinforcing its appeal to income-focused investors. Why GILD surged to 52-week highs Dividend-paying biotech stock article
• Neutral Sentiment: Gilead plans to present at upcoming fourth-quarter investor conferences, potentially giving management an opportunity to provide updates on its pipeline, commercial performance, and guidance. Gilead investor conference presentations
• Neutral Sentiment: A peer comparison and a separate analyst rating update provide additional valuation context, but the available headlines do not specify enough detail to determine a direct effect on GILD. Gilead and rivals comparison Gilead analyst rating update
• Negative Sentiment: Gilead’s third-quarter outlook contains a cautionary element: revenue guidance was raised, but the EPS outlook worsened. That contradiction may limit gains if investors focus on margins, expenses, or earnings quality despite the strength of the HIV business. Gilead third-quarter earnings analysis

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.